Cited by 2,472Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and ApplicationsStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Open access

Seymour, Lesley, Bogaerts, Jan, Perrone, Andrea, Ford, Robert, Schwartz, Lawrence H, Mandrekar, Sumithra, Lin, Nancy U, Litière, Saskia, Dancey, Janet, Chen, Alice, Hodi, F Stephen, Therasse, Patrick, Hoekstra, Otto S, Shankar, Lalitha K, Wolchok, Jedd D, Ballinger, Marcus, Caramella, Caroline, de Vries, Elisabeth G E·2017·The Lancet Oncology

DOI 10.1016/s1470-2045(17)30074-8PMC PMC5648544

Open this paper in CoChat — free account

Abstract

Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30074-8

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citation
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citation
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Show all 37 references

Sorted by citations

Items 201–300 of 1,001

Radiomics in Renal Cell Carcinoma—A Systematic Review and Meta-Analysis
Mühlbauer, J., Egen, L., Kowalewski, K., Grilli, M., Walach, M. T., Westhoff, N., Nuhn, P., Laqua, F. C., Baeßler, B., & KRIEGMAIR, M. C. (2021) · Cancers · doi:10.3390/cancers13061348 · Cited by 98
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective
Elkassem, A. M. A., Lo, S. S.-M., Gunn, A. J., Shuch, B. M., DeWitt-Foy, M. E., Abouassaly, R., Vaidya, S. S., Clark, J. I., Louie, A. V., Siva, S., et al. (2021) · Radiographics · doi:10.1148/rg.2021200202 · Cited by 94
Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond
Nishino, M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201441 · Cited by 94
RETRACTED ARTICLE: MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer
Han, J., Qu, H., Han, M., Ding, Y., Xie, M., Hu, J., Chen, Y., & Dong, H. (2020) · Oncogene · doi:10.1038/s41388-020-01574-8 · Cited by 92
Retracted
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 108
“53) and iRECIST 54 when applicable at 3 months, 6 months and 12 months.”
Imaging for the diagnosis and response assessment of renal tumours
Rossi, S. H., Prezzi, D., Kelly‐Morland, C., & Goh, V. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2342-3 · Cited by 91
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Matos, I. G., Martín-Liberal, J., García-Ruiz, A., Hierro, C., de Olza, M. O., Viaplana, C., Azaro, A., Vieito, M., Braña, I., Mur, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2226 · Cited by 92
Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT
Castello, A., Rossi, S., Mazziotti, E., Toschi, L., & Lopci, E. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237768 · Cited by 91
Immune-related tumour response assessment criteria: a comprehensive review
Somarouthu, B., Lee, S. I., Urban, T., Sadow, C. A., Harris, G. J., & Kambadakone, A. R. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170457 · Cited by 90
Immunotherapy and the role of imaging
Carter, B. W., Bhosale, P., & Yang, W. T. (2018) · Cancer · doi:10.1002/cncr.31349 · Cited by 88
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Eguren‐Santamaría, I., Sanmamed, M. F., Goldberg, S. B., Kluger, H. M., Idoate, M. A., Lu, B. Y., Corral, J., Schalper, K. A., Herbst, R. S., & Bazo, I. G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0798 · Cited by 90
Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
Duhamel, C., Ilie, M. D., Salle, H., Nassouri, S., Gaillard, S., Deluche, É., Assaker, R., Mortier, L., Cortet, C., & Raverot, G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030088 · Cited by 89
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 94
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02126-1 · Cited by 89
Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome
Nishino, M., Dahlberg, S. E., Adeni, A. E., Lydon, C., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1434 · Cited by 89
Self-citation
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Abu‐Sbeih, H., Ali, F. S., Qiao, W., Lü, Y., Patel, S. P., Diab, A. K., & Wang, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02303-1 · Cited by 88
18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns
Humbert, O., Cadour, N., Paquet, M., Schiappa, R., Poudenx, M., Chardin, D., Borchiellini, D., Benisvy, D., Ouvrier, M. J., Zwarthoed, C., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04573-4 · Cited by 88
The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
Tao, X., Li, N., Wu, N., He, J., Ying, J., Gao, S., Wang, S., Wang, J., Wang, Z., Ling, Y., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04711-3 · Cited by 89
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
Jankú, F., Han, S., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P., Subramanian, K. K., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0722 · Cited by 92
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Zeng, J., Li, X., Sander, M., Zhang, H., Yan, G., & Lin, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721830 · Cited by 89
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 86
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 88
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Leprieur, E. G., Herbretau, G., Duménil, C., Julié, C., Giraud, V., Labrune, S., Dumoulin, J., Tisserand, J. C., Emile, J., Blons, H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424675 · Cited by 85
The Impact of Beta Blockers on Survival Outcomes in Patients With Non–small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Oh, M. S., Guzner, A., Wainwright, D. A., Mohindra, N. A., Chae, Y. K., Behdad, A., & Villaflor, V. M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.016 · Cited by 85
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
Soria, F., Beleni, A.-I., D’Andrea, D., Resch, I., Gust, K. M., Gontero, P., & Shariat, S. F. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2264-0 · Cited by 84
Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors
Okoye, I., Xu, L., Motamedi, M., Parashar, P., Walker, J. W. T., & Elahi, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001849 · Cited by 81
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 91
“Although several alternative criteria have been described to account for the atypical patterns of radiographic findings sometimes seen with immuno-therapy, 22–24 these measures are still not routinely used as endpoints in registration trials.”
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84
Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
Bruno, R., Bottino, D. C., de Alwis, D. P., Fojo, A. T., Guedj, J., Liu, C., Swanson, K. R., Zheng, J., Zheng, Y., & Jin, J. Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0287 · Cited by 90
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
Huh, W. K., Brady, W. E., Fracasso, P. M., Dizon, D. S., Powell, M. A., Monk, B. J., Leath, C. A., Landrum, L. M., Tanner, E. J., Crane, E. K., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.493 · Cited by 82
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
Cohen, R., Bennouna, J., Meurisse, A., Tournigand, C., de la Fouchardière, C., Tougeron, D., Borg, C., Mazard, T., Chibaudel, B., Garcia‐Larnicol, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001499 · Cited by 82
Pitfalls in the radiological response assessment of immunotherapy
Beer, L., Hochmair, M. J., & Prosch, H. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0389-x · Cited by 81
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 79
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 80
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
Klümper, N., Saal, J., Berner, F., Lichtensteiger, C., Wyss, N., Heine, A., Bauernfeind, F. G., Ellinger, J., Brossart, P., Diem, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004024 · Cited by 81
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
de Vries, E. G. E., de Ruijter, L. K., Hooge, M. N. L., Dierckx, R. A. J. O., Elias, S. G., & Oosting, S. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0123-y · Cited by 82
In vivo Imaging Technologies to Monitor the Immune System
McCarthy, C. E., White, J. M., Viola, N. T., & Gibson, H. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01067 · Cited by 80
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 82
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
Beasley, G. M., Nair, S. K., Farrow, N. E., Landa, K., Selim, M. A., Wiggs, C. A., Jung, S., Bigner, D. D., Kelly, A. T., Gromeier, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002203 · Cited by 80
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
Saini, K. S., & Twelves, C. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01319-8 · Cited by 80
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
Jreige, M., Letovanec, I., Chaba, K., Renaud, S., Rusakiewicz, S., Cristina, V., Peters, S., Krueger, T., de Leval, L., Kandalaft, L. E., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04348-x · Cited by 79
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek, J. J., Kato, S., Ferrara, R., Russo, G. L., & Kurzrock, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0636 · Cited by 82
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
Goldmacher, G., Khilnani, A. D., Andtbacka, R. H. I., Luke, J. J., Hodi, F. S., Marabelle, A., Harrington, K. J., Perrone, A., Tse, A. N., Madoff, D. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02985 · Cited by 80
Self-citation
New Era in the Management of Melanoma Brain Metastases
Tawbi, H. A., Boutros, C., Kok, D. L., Robert, C., & McArthur, G. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200819 · Cited by 83
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
Vento, J. A., Mulgaonkar, A., Woolford, L., Nham, K., Christie, A. L., Bagrodia, A., de Leon, A. D., Hannan, R., Bowman, I. A., McKay, R. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0607-z · Cited by 77
The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II
Huang, W., Chen, Y., Fedorov, A., Li, X., Jajamovich, G. H., Malyarenko, D. I., Aryal, M. P., LaViolette, P. S., Oborski, M. J., O’Sullivan, F., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00027 · Cited by 79
Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer
Shroff, G. S., de Groot, P. M., Papadimitrakopoulou, V. A., Truong, M. T., & Carter, B. W. (2018) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2018.01.012 · Cited by 78
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Palaia, I., Tomao, F., Sassu, C. M., Musacchio, L., & Panici, P. B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s205950 · Cited by 84
Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy
Humbert, O., & Chardin, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566297 · Cited by 79
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC
Chen, M., Lu, H., Copley, S. J., Han, Y., Logan, A., Viola, P., Cortellini, A., Pinato, D. J., Power, D., & Aboagye, E. O. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.089 · Cited by 77
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 80
Self-citation
Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
Oosting, S., & Haddad, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00815 · Cited by 63
First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Siu, L. L., Wang, D., Hilton, J., Geva, R., Rasco, D., Perets, R., Abraham, A. K., Wilson, D. C., Markensohn, J. F., Lunceford, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2160 · Cited by 81
Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy
Zhou, H., Wang, Y., Xu, H., Shen, X., Zhang, T., Zhou, X. M., Zeng, Y., Li, K., Zhang, L., Zhu, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161065 · Cited by 77
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
Chan, L., Hwang, S. J. E., Byth, K., Kyaw, M., Carlino, M. S., Chou, S., & Fernández‐Peñas, P. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.035 · Cited by 75
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Litière, S., Isaac, G., de Vries, E. G. E., Bogaerts, J., Chen, A. P., Dancey, J. E., Ford, R., Gwyther, S. J., Hoekstra, O. S., Huang, E. P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01100 · Cited by 74
Self-citation
iRECIST: how to do it
ten Persigehl, T., Lennartz, S., & Schwartz, L. H. (2020) · Cancer Imaging · doi:10.1186/s40644-019-0281-x · Cited by 74
Self-citation
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Silva, D. M. D., Enserro, D. M., Mayadev, J., Skeate, J. G., Matsuo, K., Pham, H. Q., Lankes, H. A., Moxley, K. M., Ghamande, S. A., Lin, Y. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0776 · Cited by 75
Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors
Johnson, M. L., Braiteh, F., Grilley‐Olson, J. E., Chou, J., Davda, J. P., Forgie, A. J., Li, R., Jacobs, I. A., Kazazi, F., & Hu‐Lieskovan, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0836 · Cited by 74
Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Triozzi, P. L., Stirling, E. R., Song, Q., Westwood, B., Kooshki, M., Forbes, M. E., Holbrook, B. C., Cook, K. L., Alexander‐Miller, M. A., Miller, L. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3114 · Cited by 76
Results and challenges of immune checkpoint inhibitors in colorectal cancer
Emambux, S., Tachon, G., Junca, A., & Tougeron, D. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445222 · Cited by 74
Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma
Sundahl, N., Seremet, T., Dorpe, J. V., Neyns, B., Ferdinande, L., Meireson, A., Brochez, L., Krüse, V., & Ost, P. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.03.041 · Cited by 73
Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study
Ogata, T., Satake, H., Ogata, M., Hatachi, Y., Inoue, K., Hamada, M., & Yasui, H. (2018) · Oncotarget · doi:10.18632/oncotarget.26145 · Cited by 72
Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival
Ota, Y., Takahari, D., Suzuki, T., Osumi, H., Nakayama, I., Oki, A., Wakatsuki, T., Ichimura, T., Ogura, M., Shinozaki, E., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04023-w · Cited by 72
Melanoma brain metastases – Interdisciplinary management recommendations 2020
Gutzmer, R., Vordermark, D., Hassel, J. C., Krex, D., Wendl, C. M., Schadendorf, D., Sickmann, T., Rieken, S., Pukrop, T., Höeller, C., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102083 · Cited by 73
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Gyawali, B., de Vries, E. G. E., Dafni, U. G., Amaral, T. M. S., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez‐Roca, C., Kiesewetter, B., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100117 · Cited by 73
Self-citation
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Zhou, C., Hu, Y., Arkania, E., Kılıçkap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.004 · Cited by 72
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0416 · Cited by 73
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
Eichhorn, F., Klotz, L. V., Bischoff, H. G., Thomas, M., Lasitschka, F., Winter, H., Hoffmann, H., & Eichhorn, M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5624-2 · Cited by 73
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
Park, C., Na, K. J., Choi, H., Ock, C., Ha, S., Kim, M., Park, S., Keam, B., Kim, T. M., Paeng, J. C., et al. (2020) · Theranostics · doi:10.7150/thno.50283 · Cited by 71
Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications
Decazes, P., & Bohn, P. (2020) · Cancers · doi:10.3390/cancers12020371 · Cited by 74
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Colle, R., Radzik, A., Cohen, R., Pellat, A., López‐Trabada, D., Cachanado, M., Duval, A., Svrcek, M., Menu, Y., & André, T. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.009 · Cited by 70
The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives
Owens, C., Hindocha, S., Lee, R., Millard, T., & Sharma, B. (2023) · British Journal of Radiology · doi:10.1259/bjr.20220339 · Cited by 76
Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0411 · Cited by 71
“24, 25, 27, 28; details in Supplementary Tables S5 – S9 of trial protocol: Supplementary Appendix).”
BackgroundMethod
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 74
Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications
Bera, K., Velcheti, V., & Madabhushi, A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199747 · Cited by 69
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Mahalingam, D., Wang, J. S.-Z., Hamilton, E. P., Sarantopoulos, J., Nemunaitis, J. J., Weems, G. A., Carter, L., Hu, X., Schreeder, M. T., & Wilkins, H. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3185 · Cited by 69
[18F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
Valentinuzzi, D., Vrankar, M., Boc, N., Ahac, V., Zupančič, Ž., Unk, M., Škalič, K., Žagar, I., Studen, A., Simončič, U., et al. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0042 · Cited by 68
Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Liu, Y., Wu, M., Zhang, Y., Luo, Y., He, S., Wang, Y., Chen, F., Liu, Y., Yang, Q., Li, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657615 · Cited by 70
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Claret, L., Jin, J. Y., Ferté, C., Winter, H. R., Girish, S., Stroh, M., He, P., Ballinger, M. D., Sandler, A. B., Joshi, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3662 · Cited by 71
Self-citation
Do immune checkpoint inhibitors need new studies methodology?
Ferrara, R., Pilotto, S., Caccese, M., Grizzi, G., Sperduti, I., Giannarelli, D., Milella, M., Besse, B., Tortora, G., & Bria, E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.131 · Cited by 69
Mathematical modeling of cancer immunotherapy for personalized clinical translation
Butner, J. D., Dogra, P., Chung, C. D., Pasqualini, R., Arap, W., Lowengrub, J. S., Vittorio Cristini, C., & Wang, Z. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00377-z · Cited by 71
Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond
Rufibach, K. (2018) · Pharmaceutical Statistics · doi:10.1002/pst.1917 · Cited by 67
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
Global Challenges for Cancer Imaging
Schlemmer, H., Bittencourt, L. K., D’Anastasi, M., Domingues, R. C., Khong, P., Lockhat, Z. I., Muellner, A., Reiser, M. F., Schilsky, R. L., & Hricak, H. (2017) · Journal of Global Oncology · doi:10.1200/jgo.17.00036 · Cited by 66
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Jiang, X., Dudzinski, S. O., Beckermann, K. E., Young, K. L., McKinley, E. T., McIntyre, J. O., Rathmell, J. C., Xu, J., & Gore, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000328 · Cited by 65
Lactylation‐Driven NUPR1 Promotes Immunosuppression of Tumor‐Infiltrating Macrophages in Hepatocellular Carcinoma
Cai, J., Zhang, P., Cai, Y., Zhu, G., Chen, S., Song, L., Du, J.-X., Wang, B., Dai, W., Zhou, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202413095 · Cited by 75
Evaluation of liver tumour response by imaging
Grégory, J., Burgio, M. D., Corrias, G., Vilgrain, V., & Ronot, M. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100100 · Cited by 65
Immuno-oncology trends: preclinical models, biomarkers, and clinical development
Franklin, M. R., Platero, S. J., Saini, K. S., Curigliano, G., & Anderson, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003231 · Cited by 69
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Walia, A., Tuia, J. E., & Prasad, V. K. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00823-5 · Cited by 65
“Moreover, multiple radiographic response guidelines, including irRC 41 , irRECIST 42 and iRECIST 43 , have been developed with the specific aim of better accounting for the atypical patterns of tumour response that can occur with immunotherapies, such as pseudoprogression (an initial increase in…”
Background
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Unterrainer, M., Ruzicka, M., Fabritius, M. P., Mittlmeier, L. M., Winkelmann, M., Rübenthaler, J., Brendel, M., Subklewe, M. S., von Bergwelt‐Baildon, M., Ricke, J., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00190-1 · Cited by 66
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
Zhou, J., Donaubauer, A.-J., Frey, B., Becker, I., Rutzner, S., Eckstein, M., Sun, R., Ma, H., Schubert, P., Schweizer, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001845 · Cited by 67
KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Tabernero, J. M., Bang, Y., Cutsem, E. V., Fuchs, C. S., Janjigian, Y. Y., Bhagia, P., Li, K., Adelberg, D. E., & Qin, S. (2021) · Future Oncology · doi:10.2217/fon-2021-0176 · Cited by 63
Cancer immunomodulation using bispecific aptamers
Thomas, B. J., Porciani, D., & Burke, D. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.008 · Cited by 62
CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response
Wu, Z., Zhou, J., Xiao, Y., Ming, J., Zhou, J., Dong, F., Zhou, X., Xu, Z., Zhao, X., Lei, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865596 · Cited by 65
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET
Schwenck, J., Schörg, B. F., Fiz, F., Sonanini, D., Forschner, A., Eigentler, T., Weide, B., Martella, M., González-Menéndez, I., Campi, C., et al. (2019) · Theranostics · doi:10.7150/thno.35989 · Cited by 62
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 64

Authors: Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., Hodi, F. S., Therasse, P., Hoekstra, O. S., Shankar, L. K., Wolchok, J. D., Ballinger, M., Caramella, C., & de Vries, E. G. E.
Affiliations: Queen's University (CA)
European Organisation for Research and Treatment of Cancer (BE)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
NewYork–Presbyterian Hospital (US)
Mayo Clinic (US)
National Institutes of Health (US)
Harvard University (US)
Institut de Recherches Internationales Servier (France) (FR)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Memorial Sloan Kettering Cancer Center (US)
Genentech (US)
Institut Gustave Roussy (FR)
Corresponding author: Seymour, Lesley
ORCID: Seymour, Lesley
Bogaerts, Jan
Ford, Robert
Mandrekar, Sumithra
Litière, Saskia
Dancey, Janet
Chen, Alice
Hodi, F Stephen
Hoekstra, Otto S
Shankar, Lalitha K
Wolchok, Jedd D
Caramella, Caroline
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2017-03
Volume: 18
Issue: 3
Pages: e143-e152
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(17)30074-8
PMC: PMC5648544
OpenAlex: W2592144107
Cited by: 2,472
References: 37
Citations by year: 2026: 264 · 2025: 267 · 2024: 319 · 2023: 305 · 2022: 270 · 2021: 308 · 2020: 304 · 2019: 223 · 2018: 146 · 2017: 62
FWCI: 21.17
Type: journal article
Language: en
Update notices: erratum (2019-05-01)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Pure Amsterdam UMC (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (U10CA011488, P30CA008748)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: iRECIST, cancer immunotherapy, response evaluation criteria, disease progression, immunomodulators, clinical trial data collection, data warehouse
MeSH terms: Humans, Immunotherapy, Neoplasms, Practice Guidelines as Topic, Disease Progression, Tumor Burden, Response Evaluation Criteria in Solid Tumors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks